Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 17:10:1097694.
doi: 10.3389/fmolb.2023.1097694. eCollection 2023.

Clinical implications of lncRNA LINC-PINT in cancer

Ihtisham Bukhari  1 , Muhammad Riaz Khan  2 , Fazhan Li  1 , Bartlomiej Swiatczak  3 , Rick Francis Thorne  4 , Pengyuan Zheng  1 , Yang Mi  1
Affiliations

Clinical implications of lncRNA LINC-PINT in cancer

Ihtisham Bukhari et al. Front Mol Biosci. .

Abstract

Long noncoding RNAs (lncRNAs) possess the potential for therapeutic targeting to treat many disorders, including cancers. Several RNA-based therapeutics (ASOs and small interfering RNAs) have gained FDA approval over the past decade. And with their potent effects, lncRNA-based therapeutics are of emerging significance. One important lncRNA target is LINC-PINT, with its universalized functions and relationship with the famous tumor suppressor gene TP53. Establishing clinical relevance, much like p53, the tumor suppressor activity of LINC-PINT is implicated in cancer progression. Moreover, several molecular targets of LINC-PINT are directly or indirectly used in routine clinical practice. We further associate LINC-PINT with immune responses in colon adenocarcinoma, proposing the potential utility of LINC-PINT as a novel biomarker of immune checkpoint inhibitors. Collectively, current evidence suggests LINC-PINT can be considered for use as a diagnostic/prognostic marker for cancer and several other diseases.

Keywords: Cancer biomarkers; Cancer therapy; Colon adenocarcinoma (CAC); Immune checkpoint inhibitors; LINC-PINT; LncRNA; PINTology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Clinical potentials of LINC-PINT. (A) Overview of the clinical applications of LINC-PINT. In short, it can be used as a prognostic marker to ascertain the course of cancer progression based on its expression level. It can also be used as a diagnostic marker to aid the early detection of ontological transformation. The third type of application, already in pre-clinical testing, predicts response to cancer therapy. Finally, less explored but equally important is the potential of LINC-PINT-based studies to determine the susceptibility of healthy subjects to cancer. These applications can be used, in turn, to tailor and administer suitable lncRNA-based cancer therapies. Correlation of LINC-PINT expression with (B) Overall survival and (C) Disease-free survival in Colon Adenocarcinoma (D) Association of LINC-PINT expression with immune scores, including stromal, immune, and ESTIMATE scores, (E) Tumor Mutation Burden, and (F–G) microsatellite instability in colon adenocarcinoma patients.
FIGURE 2
FIGURE 2
Relationship between LINC-PINT and clinical characteristics of patients with COAD. (A) Boxplot of differences in LINC-PINT expression levels between metastatic and non-metastatic groups of COAD patients. M0: non-metastasis; M1: tumor metastasis. (B, C) The immunophenotype scores in the low-LINC-PINT group and high-LINC-PINT group. (D) The TIDE score distribution between high- and low- LINC-PINT groups. (E–N) Drug sensitivity analysis of multiple chemotherapeutic drugs in the high LINC-PINT expression group and the low LINC-PINT expression group, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ali T., Grote P. (2020). Beyond the RNA-dependent function of LncRNA genes. Elife 9, e60583. 10.7554/eLife.60583 - DOI - PMC - PubMed
    1. Anderson K. M., Anderson D. M. (2022). LncRNAs at the heart of development and disease. Mamm. Genome 33, 354–365. 10.1007/s00335-021-09937-6 - DOI - PubMed
    1. Bi X., Guo X. H., Mo B. Y., Wang M. L., Luo X. Q., Chen Y. X., et al. (2019). LncRNA PICSAR promotes cell proliferation, migration and invasion of fibroblast-like synoviocytes by sponging miRNA-4701-5p in rheumatoid arthritis. EBioMedicine 50, 408–420. 10.1016/j.ebiom.2019.11.024 - DOI - PMC - PubMed
    1. Brutovsky B. (2022). Scales of cancer evolution: Selfish genome or cooperating cells? Cancers (Basel) 14, 3253. 10.3390/cancers14133253 - DOI - PMC - PubMed
    1. Bukhari I., Khan M. R., Hussain M. A., Thorne R. F., Yu Y., Zhang B., et al. (2022). PINTology: A short history of the lncRNA LINC-PINT in different diseases. Wiley Interdiscip. Rev. RNA 13, e1705. 10.1002/wrna.1705 - DOI - PubMed

Grants and funding

This work was supported by Zhengzhou Major Collaborative Innovation Project (No.18XTZX12003); Key projects of discipline construction in Zhengzhou University (No. XKZDJC202001); National Key Research and development program in China (No.2020YFC2006100); Medical service capacity improvement project of Henan Province in China (grant number Yu Wei Medicine [2017] No.66).